Time until relapse in tuberculosis treatment trials: Implication for phase 3 trial design

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 5, 2012, Pages 464-

  Johnson, John L ^a   Thiel, Bonnie A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

DRUG SENSITIVITY; FOLLOW UP; HUMAN; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REINFECTION; RELAPSE; SPUTUM CULTURE; STUDY DESIGN; TIME; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 84865813010     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.186.5.464     Document Type: Letter

References (2)

1. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010;14: 241-242.
2. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009;180:558-563.